Emicizumab for Hemophilia A with Inhibitors: Effectiveness and Value

Questions for Deliberation and Voting: March 29, 2018 Public Meeting

These questions are for the deliberation of the New England CEPAC voting body at the public meeting.

Patient population for all questions: Patients with hemophilia A with inhibitors to factor VIII who will not be treated with immune tolerance induction (ITI) or for whom ITI has been unsuccessful. When necessary, age ranges are specified in voting questions.

Comparative Clinical Evidence

1. Is the evidence adequate to demonstrate that prophylactic emicizumab provides a net health benefit compared with no prophylactic therapy?
   
   For patients < 12 years of age  Yes  No
   For patients ≥ 12 years of age  Yes  No

2. Is the evidence adequate to demonstrate that prophylactic emicizumab provides net health benefits compared with prophylactic therapy with bypassing agents (BPAs)?
   
   For patients < 12 years of age  Yes  No
   For patients ≥ 12 years of age  Yes  No
Other Benefits and Contextual Considerations

3. When compared to prophylactic therapy with BPAs, does emicizumab offer one or more of the following “other benefits”? (select all that apply)

   a. This intervention offers reduced complexity that will significantly improve patient outcomes.
   b. This intervention will reduce important health disparities across racial, ethnic, gender, socioeconomic, or regional categories.
   c. This intervention will significantly reduce caregiver or broader family burden.
   d. This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients who have failed other available treatments.
   e. This intervention will have a significant impact on improving patients’ ability to return to work and/or their overall productivity.
   f. This intervention will have a significant positive impact outside the family, including on schools and/or communities.
   g. This intervention will have a significant impact on the entire “infrastructure” of care, including effects on screening for affected patients, on the sensitization of clinicians, and on the dissemination of understanding about the condition, that may revolutionize how patients are cared for in many ways that extend beyond the treatment itself.
   h. There are other important benefits or disadvantages that should have an important role in judgments of the value of this intervention: ______________

4. Are any of the following contextual consideration important in assessing emicizumab’s long-term value for money? (select all that apply)

   a. This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.
   b. This intervention is intended for the care of individuals with a condition that represents a particularly high lifetime burden of illness.
   c. This intervention is the first to offer any improvement for patients with this condition.
   d. Compared to prophylactic therapy with BPAs, there is significant uncertainty about the long-term risk of serious side effects of this intervention.
   e. Compared to prophylactic therapy with BPAs, there is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.
   f. There are additional contextual considerations that should have an important role in judgments of the value of this intervention: __________________________.